Baxter and Momenta $33m collaboration on biosimilars
This article was originally published in Scrip
Executive Summary
Baxter and Momenta have entered into a global collaboration to develop and commercialise biosimilars, with Baxter paying $33 million upfront for up to six follow-on biologic compounds.